Natco Pharma Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/sctcyjo5evlv462o93u28wq4.pdf

Key Takeaways


Revlimid: The End of a Windfall

Rajeev Nannapaneni: "I think this quarter we have done extremely well. I think that is reflected in the numbers. Regarding Q3 and Q4, we are not expecting much. I think we are seeing more competition. I am not expecting much. I think in our budgeting, we have not kept much revenue from Lenalidomide."

Pipeline & Launches: A Dull FY27, Then a Pickup

Rajeev Nannapaneni: "I think you should expect in '26, '27 we will have one or two, but bigger launches are happening in '27, '28. So, '26, '27 will be a little dull, but I think '27, '28 on, things will pick up."

Semaglutide: India First, US Later

Rajeev Nannapaneni: "US, any day. US, by far. There is no comparison. It is 100x difference."

Adcock Ingram: Diversification at a Rational Price

Rajeev Nannapaneni: "That asset has to perform 4x better than just to meet my South Africa investment."

Base Business & Segments: Steady, With Niche Wins


Capital Allocation & Investments

Rajeev Nannapaneni: "I mean, obviously the biggest exciting one is the eGenesis one, which is the kidney transplant, where they are taking a genetic engineered pig and putting it in a human. And one of the patients actually lived for more than six months and another patient is still comfortable, so, he is on the pig kidney. So, these are very disruptive investments, my friend."

Guidance & Commitments

CommitmentSpecificsTimeline
Quarterly revenue run rate₹750–800 cr per quarterQ3 FY26 and Q4 FY26
Quarterly PAT run rate₹135–150 cr per quarterQ3 FY26 and Q4 FY26
Full-year PAT₹1,275–1,300 crFY26
Base business growth10–15% annual growthOngoing, annual
Semaglutide India filingFile for approvalEarly January 2026
Semaglutide India launchFirst generic waveMarch–April 2026
Para-IV filingsThree to four new filingsNext few months
US launch pickupBigger launches beginFY27–28
Adcock profit consolidationFull quarter as associate (36%)Q3 FY26 onward
CTPR demerger and listingSeparate listing of demerged entityPossibly sometime in 2026
Crop/agro demerger and listingSeparate listing of demerged entityPossibly sometime in 2026

Key Metrics

MetricQ2 FY26
Consolidated total revenue₹1,463 cr, versus ₹1,434.9 cr in Q2 FY25
EBITDA₹679.2 cr, margin at 46.4%
PAT (H1 FY26)₹998 cr (per management)
Full-year PAT guidance₹1,275–1,300 cr, H2 guidance of ₹275–300 cr
Quarterly revenue run-rate guidance (H2)₹750–800 cr per quarter
Quarterly PAT guidance (H2)₹135–150 cr per quarter, including Adcock Ingram
Interim dividend₹1.5 per equity share of ₹2 face value
API segment revenue₹53.9 cr
CTPR (Crop Health) business revenue₹52 cr, close to EBITDA positive
Base business growth expectation10–15% per year
Net cash expected post-Adcock acquisition₹2,700–2,800 cr, spent ₹1,600 cr cash on Adcock, borrowed ₹400 cr
Adcock Ingram steady-state salesUS$550 million, PAT around US$46 million, Natco consolidates ~36%
Adcock Ingram acquisition multiple10x–12x EBITDA
South Africa contribution to base earnings25–30% expected
R&D and small investments annual spend₹40–50 cr per year, not exceeding